Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a clinical diagnosis of Tourette Syndrome (TS)~2. Have at least moderate tic severity~3. Have TS symptoms that impair school, occupational, and/or social function~4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder \[OCD\], Attention-Deficit Hyperactivity Disorder \[ADHD\]), be on stable doses~5. Be in good general health~6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen~7. Subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study~Exclusion Criteria:~1. Have an active, clinically significant unstable medical condition within 1 month prior to screening~2. Have a known history of long QT syndrome or cardiac arrhythmia~3. Have a known history of neuroleptic malignant syndrome~4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)~5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors~6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening~7. Have a known history of substance dependence, substance (drug) or alcohol abuse~8. Have a significant risk of suicidal or violent behavior~9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study~10. Have received an investigational drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study~11. Have previously participated in an NBI-98854 clinical study, except for NBI-98854-1403 or NBI-98854-1501.~12. Have HIV, hepatitis B, or hepatitis C

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Pre-randomization Valbenazine (Type: EXPERIMENTAL): Participants received valbenazine once daily for up to 12 weeks, depending on if and when randomization occured. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for participants \<50 kg and 80 mg for participants ≥50 kg to achieve an optimal dose of valbenazine for each participant.
- Randomized Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (matching valbenazine) once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.
- Randomized Valbenazine (Type: EXPERIMENTAL): Participants received their optimized dose of valbenazine once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).